Yes if the earnings leak didn't happen and the stock wasn't halted, this would have may be dropped from $52 to $46 - $47 but not to under $40 like it has imho.
Goldman Sachs analysts said in a report on Tuesday that the new study shows efficacy across age groups gives HZ/su a meaningful edge over Zostavax, and GSK's product had the potential to achieve peak sales of around 1 billionpounds ($1.5 billion) a year.
Agenus Inc. (including its subsidiaries, also referred to as “Agenus,” the .... presenting at least three productcandidates at .... Society of Clinical Oncology, or ASCO ( ASCO 2015 Conquer Cancer Foundation )
Goldman says $1.5 Billion Huge.
The Fly On the Wall
Juno Therapeutics (JUNO) Stock
Juno Therapeutics did not present at the conference.
thanks- how much does the report cost? Did you buy it on Yahoo or from Bloomberg website?
Bristol-Myers Deal Flags Three Gene-Therapy Picks
April 16, 2015
Gene therapy is getting major attention again this month with the recently announced deal between Bristol-Myers Squibb and uniQure and upcoming top-line data from Celladon’s Phase 2 CUPID 2 study in heart failure.
We believe this renewed attention to the space could be translated into growth opportunities for Celladon pivotal trial data catalyst.
( ADRO ) Strategic partners include Janssen Biotech,Novartis.,J&J
GVAX Pancreas is an important synergistic combination candidate because it is designed to induce T-cells against an array of pancreatic cancer antigens and enable a broad-based immune response and has demonstrated a favorable safety profile in clinical trials to date. ADRO expects to report top-line results from ECLIPSE in the first half of 2016.
In addition, ADRO is evaluating CRS-207 in combination with chemotherapy in unresectable malignanpleural mesothelioma and has a planned study of CRS-207 in combination with GVAX Pancreas and an anti-PD-1 checkpoint inhibitor in metastatic pancreatic cancer.
I'm a player bought
Cancer Immunotherapy Remains Hot as Aduro Biotech Doubles In Value On IPO Debut